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Abstract
Genome-wide association studies (GWAS) simultaneously investigating hundreds of thousands of single nucleotide
polymorphisms (SNP) have become a powerful tool in the investigation of new disease susceptibility loci. Haplotypes are
sometimes thought to be superior to SNPs and are promising in genetic association analyses. The application of genome-
wide haplotype analysis, however, is hindered by the complexity of haplotypes themselves and sophistication in
computation. We systematically analyzed the haplotype effects for breast cancer risk among 5,761 African American women
(3,016 cases and 2,745 controls) using a sliding window approach on the genome-wide scale. Three regions on
chromosomes 1, 4 and 18 exhibited moderate haplotype effects. Furthermore, among 21 breast cancer susceptibility loci
previously established in European populations, 10p15 and 14q24 are likely to harbor novel haplotype effects. We also
proposed a heuristic of determining the significance level and the effective number of independent tests by the
permutation analysis on chromosome 22 data. It suggests that the effective number was approximately half of the total
(7,794 out of 15,645), thus the half number could serve as a quick reference to evaluating genome-wide significance if a
similar sliding window approach of haplotype analysis is adopted in similar populations using similar genotype density.
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Introduction
Genome-wide association studies (GWAS) have been demon-
strated to have the power to detect modest to small effects of
genetic variants with various common diseases [1]. A large
number of novel SNPs have been identified and successfully
replicated in associations with complex diseases, such as cancers,
diabetes, and cardiovascular disease [2]. Meanwhile, haplotype
analysis has become a prominent example of multilocus genetic
association studies and has assisted in finding new disease
susceptibility loci [3–8]. Haplotypes consist of SNPs or other
genetic markers on the same chromosome that are inherited
together with little contemporary recombination [9]. Haplotype
information may aid GWAS in identifying new marker-phenotype
associations for several reasons [10]. First, haplotypes characterize
the exact organization of alleles along the chromosome. Although
D’ and r2 are useful in capturing the linkage disequilibrium (LD)
pattern between a pair of markers, they are hardly to be extended
to higher order of dependency among markers. As a result, LD
analysis based on underlying haplotypes can be more accurate
[11]. Second, by constructing haplotype blocks from SNPs, more
information can be incorporated into the association tests,
especially when haplotypes themselves are in closer LD with the
causal variant than any single genotyped SNP [12]. Haplotype
analysis has been reported to be superior to analysis based on
individual SNPs by simulation [13] and empirical studies [14,15].
Although haplotype analysis is seemingly appealing, its imple-
mentation on the genome wide scale is unwieldy given the
uncertainty and complexity of haplotypes [16], as well as the
difficulty of adjusting for multiple testing when hundreds of
thousands of hypotheses are being tested simultaneously. For
instance, there is no consensus in the exact definition of haplotype
blocks, making the boundaries of haplotype blocks not unambig-
uous [17]. One definition is based on D’ among neighboring SNPs
which needs to exceed a pre-specified cutoff value [18]; another
commonly implemented method requires a reduced haplotype
diversity on a chromosomal segment [19]. Unfortunately, no
method is uniformly better than the others in application [15]. We
favor a sliding window framework since haplotypes can be quickly
constructed and all genotyped SNPs are incorporated [20]. Fixed
window sizes are computationally easier and more efficient in
practice relative to varying window sizes. Mathias et al [21]
successfully identified five asthma susceptibility loci on chromo-
some 11 in African Americans via the sliding window approach, in
which the window sizes were 2–6 SNPs. Lambert et al. [22]
adopted a similar approach where 10 consecutive haplotype
tagging SNPs (htSNPs) were defined as a sliding window and
found a haplotype residing in FRMD4A gene at 10p13 with
increased risk for Alzheimer’s disease. In this paper, we scanned
throughout the 22 autosomes to search for significant haplotype
effects for breast cancer risk among 5,761 African American
women using the sliding window approach of 5 contiguous SNPs.
The haplotype effects were then compared with individual SNP
effects including genotyped and imputed SNPs at the same
chromosomal position. To determine a valid significance level,
1,000 permutations were exploited using the chromosome 22 data.
The permutation-based chromosome-wide significance level for
chromosome 22 and the effective number of independent tests
were computed from the empirical distribution of the minimum p-
values. The genome-wide significance level can then be readily
determined through Bonferroni correction by substituting the
effective number of tests for the total number of tests. While
globally significant results were not obtained, closer attention
should be paid to the regions revealed by the most significant
haplotypes on chromosomes 1, 4 and 18. We also scrutinized 21
known breast cancer risk regions [23] for potential haplotype




The Institutional Review Board at the University of Southern
California approved the study protocol. All participants gave
informed written consent at the time of blood draw.
Study Population
There were a total of 5,984 African American women included
in this study, of which 3,153 were cases with breast cancer and
2,831 were controls. The entire sample was derived from nine
epidemiological studies: (i) The Multiethnic Cohort Study (MEC)
[24]: 734 cases and 1,003 controls; (ii) The Los Angeles
component of the Women’s Contraceptive and Reproductive
Experiences Study (CARE) [25]: 380 cases and 224 controls; (iii)
The Women’s Circle of Health Study (WCHS) [26]: 272 cases and
240 controls; (iv) The San Francisco Bay Area Breast Cancer
Study (SFBCS) [27]: 172 cases and 231 controls; (v) The Northern
California Breast Cancer Family Registry (NC-BCFR) [28]: 440
cases and 53 controls; (vi) The Carolina Breast Cancer Study
(CBCS) [29]: 656 cases and 608 controls; (vii) The Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
[30]: 64 cases and 133 controls; (viii) The Nashville Breast Health
Study (NBHS) [31]: 310 cases and 186 controls; (ix) Wake Forest
University Breast Cancer Study (WFBC) [32]: 125 cases and 153
controls. All cases were African American women diagnosed with
invasive or in situ breast cancer. Controls were mainly recruited
through random digit dialing. A more detailed description of the
characteristics of each study is available in Table S1 and elsewhere
[23].
Genotyping and Quality Control
Genotyping was performed using the Illumina Human 1M-Duo
chip. Individuals whose samples had low DNA concentrations
(,20 ng/ml) were removed (n = 52). We also removed unexpect-
edly related individuals (n = 29), call rates ,95% (n = 100), African
ancestry ,5% (n = 36), and individuals of ambiguous sex (n = 6).
We excluded SNPs with call rate ,95% (n = 21,732) and minor
allele frequency (MAF) ,1% (n = 80,193). SNPs with a concor-
dance rate lower than 98% were removed too (n = 11,701). The
average concordance rate of the sample was 99.95%. Hardy-
Weinberg equilibrium (HWE) was not imposed as one of the
quality control criteria given that African Americans are known as
an admixed population [33]. Except for a SNP on chromosome 5
showing significant deviation from HWE (discussion follows in the
Results section), none of the other SNPs included in the following
analyses were severely out of HWE (Exact test p-value .161026)
[34]. The total number of SNPs remained in the analysis was
1,006,480 in 5,761 subjects (3,016 cases and 2,745 controls).
Statistical Analysis
Sliding window size. The sliding window approach was
adopted to define haplotype blocks throughout 22 autosomes for
its maximum coverage of genotyped SNPs given the exploratory
nature of the present study. The choice of the 5-SNP window was
mostly in agreement with the average block size for the HapMap
Yoruba population [in Ibadan, Nigeria (YRI), HapMap Phase II]
(Table S2). Wang et al [35] showed that based on Gabriel’s
definition of haplotype blocks [9,36], 57% of LD blocks in the YRI
Haplotype Effects on Breast Cancer Risk
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population were shorter than 10 kb and 37% of the blocks were
between 10 kb and 50 kb. For our AABC data, the universal 5-
SNP windows across 22 chromosomes achieved a comparable
distribution of haplotype block sizes, i.e., 55% of the 5-SNP
windows shorter than 10 kb and 44% between 10 kb and 50 kb
long. The distributions of haplotype block sizes defined by sliding
windows did not differ greatly by chromosome (Figure S1),
indicating that on no chromosome the 5-SNP sliding windows
have a disproportionately poor coverage of exceptionally long or
short blocks in general. Admittedly, the universal 5-SNP windows
across 22 autosomes or throughout approximately 1 million SNPs
may not comprehensively capture individual haplotype block size
variations at specific loci. It is nonetheless deemed a fairly good
approximation with some theoretical basis.
Haplotype inference. The haplotype frequencies within
each haplotype block defined by the sliding windows were
estimated using the Expectation-Maximization (E-M) algorithm
outlined by Excoffier and Slatkin [37], and Stram [38,39]. Let
lh(H) count the true, yet generally unknown, number of copies of
a haplotype h, with frequency ph, contained in the haplotype pair
H carried by a given individual, i.e., lh(H) takes possible values of
0, 1 or 2, meaning 0, 1 or 2 copies of such haplotype h in haplotype
pair H are inherited from parents; let E(lh(H)DGi) denote the
expected number of copies of each possible haplotype h given the
























(Textranslationfailed)indicates the summation is
over the haplotype pairs, H , compatible with the observed
genotype,Gi. The algorithm starts with initial haplotype frequen-
cies, p
(0)
h , and updates them iteratively. Equation (1) is the
expectation step and (2) is the maximization step of the E-M
algorithm.
Association testing. The inferred haplotype dosage esti-
mates, E(lh(H)DGi), abbreviated as l̂h, can be used individually in
a 1-degree-of-freedom (d.f.) test in testing for haplotype-specific




or a global test simultaneously fitting all haplotypes
l̂~(l̂1,l̂2,:::,l̂DH D{1) within the haplotype block defined by a







where DH D denotes the total number of possible haplotypes within
that block and the degrees of freedom of the global test in model
(4) are therefore DH D{1. In both models, X is the vector of
covariates, including age, study, and the top ten eigenvectors of
ancestral information estimated by principal components analysis
[40] to adjust for global ancestry differences. The eigenvectors are
included in the model to control for potential confounding due to
population stratification and admixture. In haplotype association
analysis, a large fraction of the inferred haplotypes can be very
rare, with frequency close to zero [41]. It is customary to discard
rare haplotypes that are less than 1% frequent to reduce the total
d.f. of the model so that the power to detect risk effects of relatively
common haplotypes can be well preserved. Suppose that there are
DH ’D haplotypes greater than 1% of frequency, where DH ’D,,DH D
holds true in many cases, the d.f. of the global test reduces to







We started with applying the global test throughout the whole
genome to agnostically search for haplotype effects following the 5-
SNP sliding window framework, while the 1 d.f. test of individual
haplotype-specific effects was performed only when a potentially
significant region was detected by the global test. For visualization
purposes, haplotype effects were compared to the effects of the
constituent SNPs at the same chromosomal region by an overlaid
Manhattan plot showing the statistical significance, presented as –
log10(p-value), of both haplotypes and SNPs. Haplotype effects
would become interesting only if a noticeable haplotype effect
peak was not accompanied by a similar significance peak involving
the constituent SNPs. For regions exhibiting considerable haplo-
type effects, they were further extended both upstream and
downstream by half of the original width to include more flanking
SNPs and haplotypes, making the extended regions twice longer
(Table S3). All possible individual haplotypes composed of 2 up to
10 SNPs (or the maximum number of genotyped SNPs contained
in the extended region, whichever is smaller) with haplotype
frequency .1% were investigated exhaustively to single out the
particular haplotype(s) explaining the significant global test. The
top individual haplotypes were further verified by a likelihood ratio
(LR) test comparing the model with both the top haplotype and
the best single SNP contained (model 6) to the nested model with




logit Pr(Yi~1Dgi,X)ð Þ~mzbggizbxX ð7Þ
where gi denotes the genotypes of the SNP carried by an individual
i and an additive excessive effect of each risk allele on the disease is
assumed. The novelty of the haplotype effects compared to the
SNP effects was assessed using a LR test with 1 d.f. We were also
interested in whether the haplotype effects could be otherwise
captured by genotype imputation in the same region. The
genotype imputation was performed by Mendel-GPU [42] using
the 1000 Genomes Projects (1 KGP) data as the reference panel
[43]. The much denser 1 KGP has a better genomic coverage of
rare and low frequency markers and is reported to be capable of
providing more statistical power to identify the underlying
associations [44]. The superiority of haplotype analysis to SNP
imputation could be highlighted by the presence of haplotype
signals where significant genotyped or imputed SNPs are absent.
In regions with the strongest haplotype effects, we also inferred
Haplotype Effects on Breast Cancer Risk
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and adjusted for the local ancestry information for each marker
residing near the haplotypes of interest (6250 kb). The local
ancestry characterizes the proportions of European and African
ancestry, represented by the posterior probabilities of carrying 0,
1, and 2 copies of a European allele at each SNP. The local
ancestry was computed by HAPMIX [45] with 240 HapMap
EUR+YRI phased founder haplotypes per chromosome as input.
The top haplotype effect was further adjusted for the inferred local
ancestry in addition to adjustment for global ancestry (i.e. using
the leading principal components), age, and study as described
above. This additional adjustment for local ancestry could help
eliminate false positive haplotype effects that were confounded by
local ancestry [46].
In addition, haplotype effects in the neighborhood of known
breast cancer risk SNPs identified predominantly in European
populations were investigated especially carefully. Twenty-one
regions (1p11, 2q35, 3p24, 5p12, 5q11, 6q14, 6q25, 8q24, 9p21,
9q31, 10p15, 10q21, 10q22, 10q26, 11p15, 11q13, 14q24, 16q12,
17q22, 19p13, and 20q11) and their associated SNPs were of
primary interest. Regions with potential of harboring unknown
haplotype effects were scrutinized by inferring all possible
individual haplotypes of frequency .1% consisting of 2–10
consecutive SNPs in the neighborhood of 6250 kb of known
breast cancer risk hits (except for 8q24, where 62 Mb was used
[47–49]). As before, the important haplotype effects were
compared with the significance of genotyped as well as with the
1 KGP imputed SNPs in the same region. The independence of
these haplotype-disease associations were further verified by LR
tests adjusting for the SNP effects from both the regionally best
SNP and the known breast cancer risk SNP. Notable haplotypes
residing in proximity to the known breast cancer risk hits were
again corrected for local ancestry inferred from the same region to
eliminate potential confounding due to local genetic ancestry
admixture.
PLINK [50] was the primary software to conduct the
association analyses. All regression models were adjusted for age,
study, and global ancestry. For important haplotypes indentified
through association analyses, local ancestry was additionally
adjusted for.
Permutation test. In order to obtain a valid significance
threshold for the global test of haplotype analysis, 1,000 replicates
of chromosome 22 data were generated by randomly shuffling the
case-control status for each individual in the sample while
maintaining the same numbers of cases and controls as in the
original data. Each replicate was analyzed using the same global
test logistic regression model to test the overall significance of
haplotype blocks defined by the same 5-SNP sliding window
(model 5). The same covariates were adjusted for as well, i.e., age,
study and global ancestry, but not local ancestry. The minimum p-
values of the global tests for haplotype block effects from 1,000
permutations were recorded and sorted in ascending order and the
fifth percentile of the 1,000 minimum p-values was considered the
permutation-based p-value so that the chromosome-wide type I
error rate equals 0.05. Following Dudbridge et al. [51], we
substituted the total number of tests with the effective number of
independent tests neff. If neff exists, then it can be inferred from the
beta distribution of the minimum p-values with parameters (1,neff )
[52].
Pr(minPƒa)~1{(1{a)neff






where C(:) is the gamma function with two parameters a,b.0.
Therefore beta distributions were fitted to the minimum p-values
from the 1,000 permutation replicates in two scenarios: (i) the
parameter a of the beta distribution is set equal to 1; (ii) both
parameters a and b are free to vary. In the second scenario, the
minimum p-values are consistent with the theoretical beta
distribution if the null hypothesis a~1 is not rejected; b can thus
be interpreted as the effective number of independent sliding
windows, neff. The parameters in the beta distribution were
estimated using maximum likelihood estimation (MLE) method.
Quantile-Quantile (QQ) plots were generated to evaluate the
goodness-of-fit of these beta distributions. The aforementioned
analysis was implemented in SAS version 9.1.2 (SAS Institute,
Cary, NC).
Results
The minimum p-values from the 1,000 permutations of
chromosome 22 data containing 15,649 genotyped SNPs ranged
between 1.5461027 and 9.4461024 with the fifth percentile being
5.5861026. So the permutation-based effective number of tests for
chromosome 22 was simply 0:057(5:58|10{6)~8,963. The
maximum likelihood estimates of the beta distribution parameters
were â~0:95 and b̂~7,426; or b̂~7,794 if a was constrained at 1.
Although the null hypothesis of equality a~1 was nominally
rejected in the former two-parameter case (p,0.01), â~0:95 was
close to 1 and the QQ plot comparing it to the Beta(1,7426)
distribution showed the majority of the data points fell on the
diagonal line, suggesting the lack of fit was not severe (Figure 1A).
When setting a~1 and experimenting with differentb’s,
i.e.7,400ƒbƒ8,300, goodness-of-fit tests based on empirical
distribution functions (EDF) statistics (Kolmogorov-Smirnov,
Cramer-von Mises and Anderson-Darling statistics) did not reject
the null hypothesis at the 0.10 significance level, implying that the
minimum p-values followed the designated beta distributions
satisfactorily (Table 1). The range of the effective numbers of tests,
7,400–8,300, included half the number of total sliding windows
(15,645=2~7822:5). The corresponding significance level under
this approximation was 0:0577,823~6:39|10{6, benchmark-
ing to the 5.7 percentile of the minimum p-values from 1,000
permutations. The QQ plot for those minimum p-values
compared to Beta (1,7823) distribution indicated the fit was
reasonably good (Figure 1B) and none of the goodness-of-fit tests
were rejected (p.0.25). We proceeded with the effective number
of independent tests equal to half of the total number of
overlapping haplotype blocks as a quick reference to spotting
potentially significant haplotype effects. The genome-wide signif-




~9:94|10{8in contrast to the Bonfer-
roni corrected genome-wide significance level
pB{G~0:0571,006,480~4:97|10{8.
In search of haplotype peaks where significant SNPs were
absent on the Manhattan plots, a region on chromosome 5
exhibited a distinct haplotype effect compared with individual
SNP associations at the same chromosomal region (Figure S2).
There were five overlapping haplotype blocks defined by 5-SNP
sliding windows with global test p-values (p = 1.7061028,
3.1661028, 1.8561027, 1.4561026, and 3.3861026, respectively)
less than any single SNP’s p-value within the same region.
Haplotype Effects on Breast Cancer Risk
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However, the most significant SNP rs6882564 (p = 1.1461024)
made up all the significant haplotypes and were noted to be
severely out of HWE (p,161027). A review of the intensity plots
for this SNP showed that rs6882564 was clearly miscalled by the
genotyping algorithm, and thus we dropped from consideration all
haplotypes that contain rs6882564, leaving no other haplotypes in
the same region genome-wide significant. No other haplotype
blocks throughout the genome had a global test p-value less than
1026. The top 10 independent genomic regions with haplotype
global test p-value between 1.6061026 and 1.5161025 are
summarized in Table S3. After visual examination of the
Manhattan plots contrasting the haplotype-specific effects with
the individual SNP effects, the remaining most significant regions
unlikely to be explained solely by SNPs were chr1:8,309,317-
8,318,147, chr4:122,325,743-122,363,114, and chr18:35,670,316-
35,683,522. Notably, on chromosome 1, the 5-SNP haplotype
AGCTG (Position: 8309317-8318147; frequency = 0.24)
(Figure 2A; Table 2) comprised of SNPs rs9628987, rs2289731,
rs12711517, rs2305016, and rs7535752, had a p-value three
orders of magnitude less than that of the most significant SNP
contained in the haplotype, rs12711517 (haplotype p = 5.0961026
vs. SNP p = 9.8861023). When conditioning on this locally most
significant SNP, the haplotype effect stayed almost unchanged
(adjusted OR = 0.82; 95% CI = 0.74–0.91) and remained the most
significant haplotype, although the adjusted haplotype specific
association p-value was less significant than that of without
adjustment for the best SNP (unadjusted haplotype p = 5.0961026
vs. adjusted haplotype p = 1.3661024). On chromosome 4, a 2-
SNP haplotype AG (Position: 122340944-122346258; frequen-
cy = 0.64) was close to two orders of magnitude more significant
than its best individual SNP, rs13116936 (3.3761027 vs.
1.0961025) (Figure 2B) and the unadjusted haplotype specific
effect was among the most significant in all top 10 independent
regions. After adjusting for the best SNP, the haplotype effect
remained significant at p = 7.5461024. A potentially interesting
finding was on chromosome 18 (Figure 2C) where a much rarer 6-
SNP haplotype AACGTT (Position: 35670316-35684521; fre-
quency = 0.03) showed an improvement of haplotype significance
with the adjusted p-value of 2.4261025 in contrast to the
unadjusted p-value of 6.9661025. The haplotype specific effect
did not alter meaningfully before and after the adjustment for the
best SNP (unadjusted OR = 1.72, 95% CI = 1.32-2.25; adjusted
OR = 1.79, 95% CI = 1.36-2.34). The carrier of one copy of this
haplotype had 1.79 times higher breast cancer risk relative to
women who did not carry it, much stronger than the best SNP
rs47995220 alone (OR = 1.23; 95% CI = 1.11-1.45). These three
novel haplotypes found on chromosomes 1, 4 and 18 were further
verified with comparison to the imputed SNPs based on the 1000
Genomes Project released data within the same chromosomal
Figure 1. Comparison of the permutation minimum p-values to theoretical beta distributions. (A). Quantile-Quantile plot comparing the
minimum p-values from 1,000 permutations on chromosome 22 data to beta(1,7426). (B). Quantile-Quantile plot comparing the minimum p-values to
beta(1,7823).
doi:10.1371/journal.pone.0057298.g001
Table 1. Fitting the minimum p-values from 1,000
permutations of chromosome 22 data to theoretical beta
distributions beta(a,b).








0.95 7426 .0.25 .0.25 .0.25
1 7794 .0.25 .0.25 .0.25
1 8500 0.044 0.061 0.039
1 8400 0.088 0.123 0.089
1 8300 0.164 0.236 0.188
1 7600 .0.25 .0.25 .0.25
1 7400 .0.25 0.16 0.116
1 7300 0.147 0.049 0.047
doi:10.1371/journal.pone.0057298.t001
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regions. None of the aforementioned novel haplotype-specific
associations could have been revealed by imputed SNPs
(Figure 3A–C). As shown in the Manhattan plots contrasting the
haplotype effects with that of the imputed SNPs, the most
significant haplotypes were independent of the neighboring
clusters of imputed SNPs; no adjacent SNPs achieved comparable
significance as the top haplotypes did. These novel haplotypes
were not confounded by local ancestry inferred from neighboring
SNPs either (Table S5). The test statistics stayed largely unchanged
after further adjusting for the local ancestry in addition to the
global ancestry for a finer correction for population admixture.
Among the remainder of the top 10 independent regions with
haplotype global test p-values less than 1.5161025, the signifi-
cance levels of the top individual haplotypes and SNPs were very
close for chromosomes 3, 5 and 10, implying that the noticeable
haplotype effects shown on the Manhattan plots can be mostly
credited to the genotyped SNPs (Figures S3 A–C). On the rest of
the chromosomes, the top SNPs were more significant than any
inferred haplotypes, so that the haplotypes did not contribute more
information towards genetic association tests in those regions than
SNPs themselves.
As noted by Chen et al [23], the endeavor to replicate the
significance of the known GWAS hits using the AABC data was
largely unsuccessful, implying the risk loci for breast cancer found
in other GWAS, predominantly of European ancestries, may not
be the same as in African Americans. For four of the known
GWAS SNPs the associations in our African American breast
cancer data had a nominally significant p-value less than 0.05
(Table S4), namely rs13387042 at 2q35 (OR = 0.89; 95%
CI = 0.82–0.97; p = 0.00713), rs865686 at 9q31 (OR = 0.92;
95% CI = 0.85–0.99; p = 0.0287), rs2981582 at 10q26
(OR = 1.11; 95% CI = 1.03–1.19; p = 0.0087), and rs2363956 at
19p13 (OR = 0.88; 95% CI = 0.82–0.95; p = 8.161024). They are
all common variants of modest effects in this study with minor
allele frequency between 0.07 and 0.49. Across these 21 regions
with known breast cancer risk, 10p15 and 14q24 showed potential
haplotype effects with the global test p-value less than 1.061024,
albeit not genome-wide significant. When scrutinizing all possible
inferred individual haplotypes of 2–10 SNPs long in the vicinity of
the known markers, a 3-SNP haplotype at 10p15, CTC (Position:
5705780–5712025; frequency = 0.22) constituted by rs17141741,
rs2386661 and rs4414128 was three orders of magnitude more
significant than the most significant individual SNP contained in
the haplotype, rs4414128 (unadjusted haplotype p-value = 561026
vs. best SNP p-value = 7.0861023) (Table 3). This haplotype was
associated with a 20% reduced risk per copy for breast cancer
relative to the women not carrying it. The haplotype-specific effect
was almost unchanged after adjustment for both the best
contained SNP (rs4414128) and the index marker (rs2380205)
(adjusted haplotype OR = 0.81, 95% CI = 0.72–0.91,
p = 2.1661024). The haplotype signal was two or three orders of
magnitude more significant than any of the remaining individual
SNPs adjacent to that haplotype, as shown from the leftmost
haplotype signal peak in Figure 4A. When further compared to the
1 KGP imputed SNPs in the same region, this CTC haplotype
was still independent of the imputed SNPs (Figure 5A). The
imputed SNPs residing within close proximity had similar
significance levels to that of the genotyped SNPs (Figure 4A vs.
Figure 5A), which emphasized that haplotype effect was unlikely to
be explained by SNP imputation either. Another 3 SNP haplotype
GAG (Position: 6042374–6043841; frequency = 0.60) was stronger
than any genotyped SNPs. However, we found an imputed SNP
(rs3181152; risk allele: G; frequency: 0.45; p = 4.7261025) that fell
on this haplotype and was an even stronger predictor of risk. The
analysis of individual haplotype effects also identified a new region
at 14q24 containing the known hit rs999737, where the most
significant haplotype was CGCAGC (Position: 68033499–
68045127; frequency = 0.05) with the unadjusted haplotype p-
value over three orders of magnitude less than that of the best
contained SNP, rs10132579 (unadjusted haplotype p = 1.6961026
vs. best SNP p = 9.5561023) (Figure 4B). It was also noted that
this haplotype effect was stable after additional adjustment for
rs10132579 and rs999737 (unadjusted OR = 0.60, 95%
CI = 0.48–0.74 and the adjusted OR = 0.60 with 95%
CI = 0.47–0.77), suggesting approximately a 40% decreased breast
cancer risk per copy was associated with this CGCAGC haplotype
among the carriers. Taking local ancestry into account did not
change the results for either the CTC haplotype on 10p15 or the
CGCAGC haplotype on 14q25 (Table S5). There were numerous
other individual haplotypes with unadjusted significance between
1026 and 1025 on 8q24 and 19p13. However, these top haplotype
effects were indistinguishable from the top SNPs. Once adjusted
Figure 2. Comparison of the significance of individual haplotypes with the most significant SNPs in three regions on chromosomes
1, 4 and 18. These three regions, namely, (A) chr1:8,309,317-8,318,147; (B) chr4:122,325,743- 122,363,114; and (C) chr18:35,670,316-35,683,522 were
identified by the genome-wide haplotype association analysis using 5-SNP sliding windows. The regions were further extended both upstream and
downstream by half of the original width to explore underdetected effects. Black circles denote individual haplotypes, the sizes of which are
proportional to their haplotype frequencies. Red dots denote genotyped SNPs within the same region. Blue dot shows the most significant SNP.
doi:10.1371/journal.pone.0057298.g002
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for the best SNP contained, these haplotypes became insignificant
(p.0.05) (Figures S4 A–D).
Discussion
We implemented a genome-wide haplotype association analysis
searching for breast cancer risk susceptibility loci in African
American women. To quickly narrow down to potential risk
regions, a 5-SNP sliding window approach was applied throughout
22 autosomes. Among approximately 1 million windows, none
achieved the genome-wide significance determined by an approx-
imation to the beta distribution of the minimum p-values through
1,000 permutations (pG = 9.94610
28). Only 10 independent
chromosomal regions had the haplotype global test p-value less
than 1.561025. The haplotype AGCTG at chromosome
1:8,309,317–8,318,147 showed a moderate haplotype effect that
was otherwise not captured by association analyses focusing on
SNPs. This region overlaps a solute carrier family 45 member 1
gene (SLC45A1, position: 8,306,977–8,326,814) that is predomi-
nantly expressed in brain tissues and is also seen frequently deleted
in brain tumor cells, suggesting a putative role as a tumor
suppressor [53], however, the clear picture of its biological
mechanism is far from complete. The 2-SNP haplotype AG on
chromosome 4:122,340,944–122,346,258 had a stronger associa-
tion with the disease than any SNPs in the same region. About
30 kb upstream of it resides TNIP3 gene (Homo sapiens
TNFAIP3 interacting protein 3). Both TNIP and TNFAIP
proteins were reported to overexpress in human carcinoma cells
and suppress the activation of nuclear factor kappa B (NF-kB)
[54]. The haplotype AACGTT at chromosome 18:35,670,316–
35,684,521 was associated with increased risk for breast cancer
and the haplotype effect was independent of individual SNP
Figure 3. Comparison of the significance of individual haplotypes with imputed SNPs in regions on chromosomes 1, 4 and 18.
Contrast of the haplotype effects with the effects of the 1000 Genome Project imputed SNPs in these three regions, namely, (A) chr1:8,309,317-
8,318,147; (B) chr4:122,325,743- 122,363,114; and (C) chr18:35,670,316-35,683,522 are shown. Black circles denote individual haplotypes, the sizes of
which are proportional to their haplotype frequencies. Red dots denote imputed SNPs within the same region. Blue dot shows the most significant
imputed SNP.
doi:10.1371/journal.pone.0057298.g003
Table 2. The most significant individual haplotypes identified in the extended regions on chromosomes 1, 4 and 18.
Unadjusted for SNP effect Adjusted for SNP effect
Chromosome Constituent SNPs Haplotype Frequency OR 95% CI Hap P OR 95% CI Hap Pa
1 rs9628987,rs2289731,rs12711517, AGCTG 0.24 0.81 (0.74–0.89) 5.09E–06 0.82 (0.74–0.91) 1.36E–04c
rs2305016,rs7535752
SNP adjustedb
rs12711517; T, 0.36; 1.11 (1.03–1.20);
p = 9.88E–03
4 rs17435444,rs13116936 AG 0.64 1.23 (1.13–1.33) 3.37E–07 1.74 (1.26–2.39) 7.54E–04c
rs13116936; T, 0.34; 0.84 (0.77–0.91);
p = 1.09E–05
18 rs7233920,rs4799278,rs12605634, AACGTT 0.03 1.72 (1.32–2.25) 6.96E–05 1.79 (1.36–2.34) 2.42E–05
rs4799520,rs7238528,rs17702736
rs4799520; A, 0.09; 1.23 (1.11–1.45);
p = 3.66E–04
athe p-value of LR test of the haplotype-specific effect after adjustment for the best SNP contained in that haplotype.
bthe rs number, risk allele and its frequency, Odds Ratios and 95% CI, and the p-value of the SNP that is adjusted for in the LR test are presented.
cThere are no individual haplotypes significant at 1.0E-4 in this region after adjustment for the best contained SNP. Instead the most significant haplotype is reported for
the sake of completeness.
doi:10.1371/journal.pone.0057298.t002
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effects, although no known genes are found nearby. Therefore,
these regions revealed by haplotype analysis are candidates for
fine-mapping to locate the casual variants as a first step towards
deciphering the true biological functions. Among the 21 known
breast cancer risk regions revealed by previous GWAS, 10p15 and
14q24 seem most likely to harbor unknown risk loci based on the
suggestive haplotype associations described above.
Figure 4. Two known breast cancer risk regions 10p15 and 14q24 exhibit putative haplotype effects. (A) 5.67–6.17 Mb region at 10p15;
(B) 67.84–68.34 Mb region at 14q24. Black circles denote individual haplotypes, the sizes of which are proportional to their haplotype frequencies.
Red dots denote genotyped SNPs within the same region. Blue dot shows the most significant SNP. Cyan dot denotes the known breast cancer risk
SNP identified by previous GWAS.
doi:10.1371/journal.pone.0057298.g004
Figure 5. Comparison of the significance of individual haplotypes with imputed SNPs in 10p15 and 14q24. (A) 5.67–6.17 Mb region in
10p15; (B) 67.84–68.34 Mb region in 14q24. Black circles denote individual haplotypes, the sizes of which are proportional to their haplotype
frequencies. Red dots denote imputed SNPs within the same region. Blue dot shows the most significant imputed SNP. Cyan dot denotes the known
breast cancer risk SNP identified by previous GWAS.
doi:10.1371/journal.pone.0057298.g005
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In previous work, Chen et al. [23] and Siddiq et al. [55] have
shown that the genome-wide significance for the 21 known breast
cancer SNPs did not replicate in African Americans. The majority
of those SNPs were discovered predominately in European
populations, with the exception of rs2046219 at 6q25 found in
the Han Chinese population. Chen et al have also shown that
many of the index risk variants for breast cancer are significant in
multiple populations except for African Americans [56]. We
confirmed that the most significant SNPs within each known
region are all different from the known breast cancer risk SNPs
(Table S4). All evidence underscores the different risk association
patterns between African Americans and European populations,
and limits the generalizability of the previously established
significant GWAS hits as well as presents new challenges in the
investigation of breast cancer susceptibility loci specifically for
African Americans.
The haplotype association tests were based on haplotype dosage
estimates inferred by the E-M algorithm from unphased genotypes
for unrelated subjects under the assumption of HWE (the
estimation step). We substituted the expected haplotype dosages
for the unknown true haplotypes and fit these continuous dosage
variables into conventional logistic regression models (l̂in models 3
through 7) (the substitution step). Even though the haplotype
inference from diploid genotypes is not free from uncertainty, the
use of these continuous dosages largely correct for the uncertainty
derived from haplotype inference and the predictability of
haplotypes is quite high, especially when adjacent SNPs are in
high LD, a condition that often satisfies in analyses focused on
haplotype blocks [38]. This simple expectation-substitution
approach [57] has been shown to have a proper control of the
type I error rate for the association test when we believe the
haplotype dosage estimates have no differential errors between
cases and controls [58]. In other words, case-control status is
unrelated to the errors in haplotype dosage estimation, which is
generally valid when haplotypes are inferred by pooling both cases
and controls and the null hypothesis of no significant association
between haplotype and disease is true. Several concerns arise
when under the alternative hypothesis a few assumptions are no
longer true. For instance, if haplotype frequencies in cases and
controls are associated with the disease status, failure to account
for haplotype uncertainty can lead to estimates biased towards to
null [59,60]. Second, even though the SNPs are in HWE in the
general population, it may not be necessarily so in the case-
enriched case-control sample so that the estimation of haplotype
dosages may not be accurately inferred from the sample’s
genotypes. To address these aforementioned issues, Lin et al.
[61,62] proposed a maximum likelihood (ML) method that
simultaneously infers haplotype frequencies and regression pa-
rameters in the same model. Their method yields less biased
estimates and the confidence intervals of the regression coefficients
have better coverage of the true value through simulation data for
a variety of settings under the alternative hypotheses. We note
however that the superiority of the ML method over the
expectation-substitution applies only to scenarios where the true
magnitude of association is very large, i.e., b= 0.9 (OR = 2.5).
Such large effects seem to be rare in GWAS of either common
SNPs or common haplotypes studied here. Another simulation
analysis [59] also verified that in practical settings where a
haplotype block formed by a small number of SNPs with limited
haplotype diversity, the bias was minimal and the empirical
confidence intervals had appropriate coverage of the true value.
More importantly, the performances of the maximum likelihood
method and the expectation-substitution were almost indistin-
guishable, implying the expectation-substitution is robust to
reasonable departure from the assumptions. Therefore, substitut-
ing the inferred haplotype dosages in the regression model still
retains good statistical properties in most practical contexts of
haplotype association tests. If haplotypes with greater risk effect
were of interest, the simultaneous maximum likelihood method
would be preferable.
We may not have had enough statistical power to identify
significant rare haplotypes or modest to weak haplotype effects
despite our large sample size. Haplotypes of less than 1%
frequency were unaddressed in our analyses mainly due to the
intrinsic difficulty and unreliability of inference of those rare
haplotypes. Uncommonly short or long haplotypes in the genome
compromise our 5-SNP sliding windows flexibility to identify them
in the haplotype global test. It is possible that constructing a larger
window may capture more haplotype variety such that some rare
haplotypes can be taken into account. Nonetheless, concerns of
computing efficiency arise as the number of SNPs increases. For
example, if the total number of heterozygous SNPs in each
haplotype block is m, there could be 2m possible haplotypes and
thus (2mz1)2m{1 possible haplotype pairs being summed over in
Table 3. The most significant individual haplotypes in 10p15 and 14q24.
Unadjusted for SNP effect Adjusted for SNP effect
Chromsome SNPs Haplotype Frequency OR 95% CI Hap P OR 95% CI Hap Pa
10p15 rs17141741,rs2386661,rs4414128 CTC 0.22 0.79 (0.72–0.88) 5.00E–06 0.81 (0.72–0.91) 2.16E–04
Known Risk SNP adjustedb
rs2380205; C, 0.42; 0.98 (0.91–1.06); p = 0.5945
Best SNP adjustedb
rs4414128; T, 0.38; 1.11 (1.03–1.21); p = 0.007084
14q24 rs765899,rs737387,rs2842347, CGCAGC 0.05 0.6 (0.48–0.74) 1.69E–06 0.6 (0.47–0.77) 4.27E–05
rs757369,rs10132579,rs2842346
rs999737; T, 0.05; 0.98 (0.82–1.17); 0.7994
rs10132579; G, 0.37; 0.89 (0.82–0.97); p = 0.009551
athe p-value of LR test of the haplotype specific effect after adjustment for both the known breast cancer risk SNP and the best SNP contained in that haplotype.
bthe rs number, risk allele and its frequency, Odds Ratios and 95% CI, and the p-value for the SNP adjusted in the LR test are presented. For the regions with known
breast cancer risk hits, both the known hit and the locally best SNP were adjusted for in the LR test for the independence of haplotype signals.
doi:10.1371/journal.pone.0057298.t003
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the E-M algorithm for each subject. The number grows
exponentially, exacerbating the feasibility of implementing the
algorithm. Even though in reality, the number of possible
haplotypes may just be a fraction of 2m, the same idea still
applies. Qin et al [63] proposed the partition ligation E-M
algorithm by breaking up a sequence of SNPs into smaller pieces,
each including 5–10 markers. In our study, in order to maximize
the coverage of all genotyped SNPs, a 5-SNP window was adopted
to construct haplotype blocks and haplotype global test was
employed therein. Arguably, varying window sizes are capable of
reflecting varying degrees of LD in the data [64,65]: more SNPs
should be included in the same haplotype block when they are in
regions of extensive LD and fewer SNPs should be portioned
together given limited LD structure. However, it is difficult to
identify regions of high and low LD and alter the window sizes
accordingly across the entire genome with high precision. It was
recommended by Mathias et al [21] that smaller window sizes be
run prior to larger windows. We employed a strategy that both
quickly narrows down to potentially important regions through the
universal 5-SNP sliding windows and permits the flexibility of
detecting underlying haplotypes of 2–10 SNPs long residing in
those regions. The choice of 5-SNP window roughly agrees with
the overall average haplotype block sizes for people of African
ancestry, in which the total number of the haplotype blocks longer
than 10 SNPs (,25 kb) should not be unexpectedly large [9].
Larger windows may improve the ability to identify unknown
haplotype effects. However, if a haplotype effect existed in a 10-
SNP block, it would have been at least partly captured by at least a
few of a series of 5-SNP blocks. Note that this should never be used
as a one-size-fits-all solution since the SNP density, underlying
haplotype diversity, and populations under investigation can be
fundamentally different from study to study. A similar exploration
of the choice of the average window size is suggested prior to
applying the sliding windows approach in other groups with
different LD patterns.
One drawback in the use of overlapping sliding windows is the
difficulty of making correct inference of the type I errors.
Obviously, overlapping windows were not independent. A naı̈ve
application of Bonferroni adjustment would incur overly conser-
vative significance levels and the power to find true positive
associations would also be compromised. Permutation tests have
been shown to be capable of drawing the significant threshold
directly from the experimental data [66] and serve as the gold
standard in the comparison of performances of various multiple
testing adjustments [67]. Nevertheless, permutation tests are
computationally very intensive and time-consuming. One thou-
sand permutations in a genome-wide haplotype analysis can take
weeks to months to finish in light of large sample sizes, haplotype
inference, and association testing. Numerous innovative recom-
mendations [67–71] have been proposed and each has its own
merits. One category among those approaches incorporates the
computation of the effective number of independent tests: neff and
use of neff in Bonferroni correction. neff can be inferred from the
beta distribution of the minimum p-values from permutation
replicates. We conjectured that in our African American sample
the true number of effective tests for chromosome 22 lies
somewhere between 7,400 and 8,300, covering half the number
of total overlapping windows. So the permutation test implies that
approximately 50% of total sliding windows can be considered
independent and therefore a modified Bonferroni correction can
be used readily.
In summary, we applied a 5-SNP sliding window approach to
perform genome-wide haplotype association analysis and identi-
fied three novel regions with potential interest for further
investigation and validation. Two of 21 known breast cancer risk
regions established in previous GWAS, namely 10p15 and 14q24,
exhibited moderate haplotype effects and warrant additional
replication work to confirm their significance in African American
women.
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Figure S1 The distributions of 5-SNP sliding window
sizes shown in cumulative density. Each colored line
denotes the 5-SNP sliding window sizes on each chromosome,
shown as cumulative density of window sizes from the smallest to
the biggest. The black curve shows the average cumulative density
across 22 autosomes. The 1, 25, 50, 75, 90, and 99 percentile of
the average window size are 1, 5, 9, 14, 20 and 32 kb, respectively.
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Figure S2 Comparison of the significance of haplotype
blocks and SNPs on chromosome 5 (97.3 Mb –97.8 Mb).
Black dots represent the significance of haplotype blocks by the
global test. Red circles denote the significance of SNPs in the same
chromosomal region. All top five haplotype blocks overlap each
other and contain SNP rs6882564, which was severely out of
Hardy-Weinberg Equilibrium.
(TIFF)
Figure S3 Comparison of the significance of individual
haplotypes with the most significant SNPs in three
regions on chromosomes 3, 5 and 10. These three regions,
namely, (A) chr3:7,220,000-7,280,000; (B) chr5:142,326,000-
142,371,000; and (C) chr10:115,105,000-115,124,000 had small
p-values in the genome-wide haplotype association analysis. Black
circles denote individual haplotypes, the sizes of which are
proportional to their haplotype frequencies. Red dots denote
genotyped SNPs within the same region. Blue dot shows the most
significant SNP. The observed top individual haplotype effects
were mostly due to the top SNPs.
(TIFF)
Figure S4 Comparison of the significance of individual
haplotypes with genotyped and imputed SNPs in 8p24
and 19p13. (A),(C) 125.99-129.99 Mb region in 8q24; (B),(D)
17.00–17.50 Mb region in 19p13. Black circles denote individual
haplotypes, the sizes of which are proportional to their haplotype
frequencies. Red dots denote genotyped SNPs in (A),(B) and
imputed SNPs in (C),(D) within the same region of haplotypes. Blue
dot shows the most significant genotyped SNP in (A),(B) and the
most significant imputed SNP in (C),(D). Cyan dot in (C),(D) denotes
the known breast cancer risk SNP identified by previous GWAS.
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